FY2025 EPS Estimates for Ekso Bionics Boosted by Analyst

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Ekso Bionics in a note issued to investors on Wednesday, December 31st. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.87) per share for the year, up from their prior forecast of ($0.92). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.10) EPS.

Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Tuesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.45. The business had revenue of $4.23 million for the quarter, compared to analysts’ expectations of $4.16 million. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%.

Other equities analysts have also issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a research note on Monday, December 22nd. Wall Street Zen raised Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.50.

Ekso Bionics Trading Up 11.5%

Shares of EKSO stock opened at $9.53 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.09 and a current ratio of 1.66. Ekso Bionics has a 52-week low of $2.73 and a 52-week high of $14.33. The company has a market capitalization of $24.97 million, a PE ratio of -1.68 and a beta of 0.71. The business’s fifty day moving average is $5.28 and its 200 day moving average is $4.46.

Insider Buying and Selling

In other Ekso Bionics news, CEO Scott G. Davis sold 23,315 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $111,912.00. Following the transaction, the chief executive officer directly owned 78,777 shares in the company, valued at $378,129.60. This trade represents a 22.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jerome Wong sold 11,288 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $4.80, for a total transaction of $54,182.40. Following the completion of the sale, the chief financial officer owned 26,009 shares of the company’s stock, valued at approximately $124,843.20. The trade was a 30.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 6.10% of the stock is owned by company insiders.

Institutional Trading of Ekso Bionics

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in shares of Ekso Bionics during the third quarter valued at about $57,000. Shay Capital LLC bought a new position in Ekso Bionics during the 3rd quarter worth approximately $67,000. Citadel Advisors LLC purchased a new position in Ekso Bionics in the 3rd quarter worth approximately $198,000. Finally, Consolidated Portfolio Review Corp purchased a new position in Ekso Bionics in the 3rd quarter worth approximately $333,000. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.